Deep Genomics

Deep Genomics

Edit info

  • Founded: 2014
  • Location: Toronto, ON
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: CNS conditions
  • Drug types: NEU, GEN
  • Lead product: Undisclosed
  • Funding: $40M B Jan 2020
  • Investors: Future Ventures, Amplitude Ventures, Magnetic Ventures, Khosla Ventures, True Ventures


deepgenomics.com

linkedin.com

job board


Business:

AI-discovery, Oligonucleotide Therapies

Drug notes:

Additional undisclosed programs RD CNS conditions, metabolic conditions, undisclosed

About:

Deep Genomics is using AI to build life-saving genetic therapeutics. Biology is too complex for the human mind to comprehend, so future drug development will depend on AI assistance. By using the revolutions in AI, RNA biology and automation, Deep Genomics is designing RNA therapies for any gene and any genetic condition. Deep Genomics’ proprietary AI Workbench identifies novel targets from evaluating thousands of possibilities to identify the best therapeutic candidates. Lead candidates have been identified for over 50% of the novel targets Deep Genomics has tested so far. Now, Deep Genomics is creating AI Workbench 3.0 to expand the number of mechanisms and genetic variants analyzed, so the company can tackle complex genetic diseases.

Deep Genomics
Head of Platform Biology
Cambridge, MA|48 days ago
Apply
Deep Genomics
Head of Platform Technology
Cambridge, MA|48 days ago
Deep Genomics
Senior Machine Learning Engineer - Accelerating Dr...
Cambridge, MA/Toronto, ON/ Remote North America|82 days ago


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com